Robert Clarke - Pulmatrix Insider

Pulmatrix Inc -- USA Stock  

USD 1.9  0.07  3.83%

CEO and President and Director

Dr. Robert W. Clarke, Ph.D., is Chief Executive Officer and Director of the Company. Dr. Clarke has served as our chief executive officer and director since June 15, 2015, and he was the chief executive officer and director of Pulmatrix Operating since July 2012. Dr. Clarke joined Pulmatrix Operating in April 2004 as its first Ph.D. scientist and served as Chief Scientific Officer from May 2011 to September 2012, where he oversaw the research and development efforts focused on the iCALM and iSPERSE technologies. Prior to joining our Company, Mr. Clarke served as an Associate Director of Life Sciences at Alkermes, Inc. focusing on the development of inhaled therapeutic products based on the Advanced Inhalation Research technology. Dr. Clarke holds a B.Sc. in Biomedical Engineering from Boston University and received his Ph.D. in Physiology from Johns Hopkins University
Age: 46  CEO Since 2015  Ph.D    
781-357-2333  http://www.pulmatrix.com
Clarke also completed postdoctoral training in Respiratory Biology at Brigham and Women?s Hospital and Harvard University. As a result of Dr. Clarke?s more than twenty years of experience in the healthcare industry and his focus on pulmonary drug delivery and the role of inhaled particles in respiratory biology and medicine, including coauthorship of over eighty chapters, papers, and abstracts, we believe that Dr. Clarke is qualified to serve as a member of the Board.

Robert Clarke Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (38.77) % which means that it has lost $38.77 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (122.79) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 4.55 M in liabilities with Debt to Equity (D/E) ratio of 28.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix Inc has Current Ratio of 1.95 which is within standard range for the sector.

Similar Executives

Entity Summary

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix Inc (PULM) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 18 people. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Pulmatrix Inc to your portfolio

Top Management

Pulmatrix Inc Leadership Team
Terrance McGuire, Director, MBA
Matthew Sherman, Director
Alexander Klibanov, Founder
David Hava, Executive, Ph.D
Akihisa Akao, Director
Michael Higgins, Director, MBA
Steven Gillis, Director
Jean Sung, President
William Duke, CFO, MBA
David Maki, Director
Robert Clarke, CEO, Ph.D
Scott Rocklage, Director, Ph.D
Kurt Graves, Director
Richard Conley, Director, MBA
Mark Iwicki, Chairman, MBA
Amit Munshi, Director, MBA
Gregory French, Director
Hojabr Alimi, Chairman
Prof Edwards, Founder
David JD, Executive

Stock Performance

Pulmatrix Performance Indicators